Inhibikase Therapeutics (IKT) Share-based Compensation (2020 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Share-based Compensation of $5.6 million for Q1 2026, up 172.24% year-over-year from $2.0 million in Q1 2025, and up 22.63% quarter-over-quarter from $4.5 million in Q4 2025.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Share-based Compensation (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Share-based Compensation for 7 consecutive years, with $5.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 172.24% year-over-year to $5.6 million; the TTM figure through Mar 2026 stood at $18.8 million (up 85.87% YoY), while the FY2025 annual figure was $43.6 million, up 435.13% from the prior year.
- Share-based Compensation climbed to $5.6 million in Q1 2026 per IKT's latest filing, from $4.5 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $7.9 million in Q4 2024 and bottomed at $30697.0 in Q2 2024.
- Historically, Share-based Compensation has averaged $1.8 million across 5 years, with a median of $129781.0 in 2023.
- Annual changes were most pronounced in 2022 — Share-based Compensation slumped 79.15% — and 2025, when it jumped 13610.6%.
- Inhibikase Therapeutics' Share-based Compensation stood at $100363.0 in 2022, then climbed by 21.81% to $122249.0 in 2023, then surged by 6369.14% to $7.9 million in 2024, then plunged by 42.67% to $4.5 million in 2025, then climbed by 22.63% to $5.6 million in 2026.
- Business Quant data shows IKT's Share-based Compensation at $5.6 million in Q1 2026, $4.5 million in Q4 2025, and $4.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 120.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 277.20 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 137.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Inhibikase Therapeutics | 435.56 Mn | 276.54 Mn | - | 5.35 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.35 Mn |
| Mar 31, 2026 | 5.56 Mn |
| Dec 31, 2025 | 4.53 Mn |
| Sep 30, 2025 | 4.53 Mn |
| Jun 30, 2025 | 4.21 Mn |
| Mar 31, 2025 | 2.04 Mn |
| Dec 31, 2024 | 7.91 Mn |
| Sep 30, 2024 | 148,024.00 |
| Jun 30, 2024 | 30,697.00 |
| Mar 31, 2024 | 53,434.00 |
| Dec 31, 2023 | 122,249.00 |
| Sep 30, 2023 | 129,781.00 |
| Jun 30, 2023 | 124,845.00 |
| Mar 31, 2023 | 123,273.00 |
| Dec 31, 2022 | 100,363.00 |
| Sep 30, 2022 | 101,788.00 |
| Jun 30, 2022 | 132,767.00 |
| Mar 31, 2022 | 123,229.00 |
| Dec 31, 2021 | 265,850.00 |
| Sep 30, 2021 | 352,419.00 |